JNJ earnings analysis — 8-K, transcript, guidance强生 (JNJ) 财报解读 — 8-K、transcript、guidance
Earnings Follow-Up Analysis
1. Actual vs Consensus: Q2 2026 non-GAAP diluted EPS hit $2.90, beating the consensus estimate of $2.84 by 2.1%; total revenue reached $25.31B, exceeding the $25.0B consensus by 1.2%, per the official business release and SEC Form 8-K filing.
2. Revenue Quality & Profitability: GAAP net income for Q2 was $5.534B, a 0.1% YoY decline, with diluted EPS of $2.27, down 0.9% YoY. Non-GAAP net income rose 5.7% YoY to $7.081B, with EBITDA at $8.3B and a 34.4% margin. Segment operational sales growth was 6.8% for Innovative Medicine and 3.6% for MedTech. The provided updated financial snapshot covers Q1 2026, with full Q2 gross margin details not disclosed.
3. Cash Flow & Balance Sheet: YTD Q2 free cash flow was ~$8.7B. As of Q1 2026 end, cash and equivalents totaled $21.7B, total debt $55.0B, and net debt $33.3B, per the SEC 8-K and updated financial statement.
4. Raised Full-Year Guidance: The company lifted 2026 non-GAAP adjusted EPS guidance to a midpoint of $11.68, a $0.13 increase from prior guidance, representing 8.2% YoY growth. Reported revenue guidance midpoint was raised to $101.1B, a 7.3% YoY increase.
5. GAAP vs Non-GAAP: The firm does not provide forward-looking GAAP guidance due to uncertainty around legal proceedings, unusual gains/losses, and other unquantifiable items. Q2 GAAP and non-GAAP EPS differ primarily due to intangible amortization and special items.
6. Management Commentary: Leadership noted Q2 operational sales growth of 5.6%, with double-digit growth excluding STELARA. Key product wins included DARZALEX (> $4B sales, ~18% YoY growth), TREMFYA (71% YoY growth), and CAPLYTA (122% YoY new patient starts). MedTech saw expanded adoption of VARIPULSE with 85k+ global AFib patients treated.
7. Unresolved Investor Questions: Missing details include segment-level GAAP revenue breakdowns, backlog/RPO data, deferred revenue, capex line-item specifics, granular demand and pricing metrics, and full quarterly GAAP financial splits.
本季度收益分析要点
1. 业绩超预期：2026年第二季度非GAAP摊薄每股收益2.90美元，超出市场一致预期2.84美元，超幅2.1%；总营收253.1亿美元，超出预期250亿美元，超幅1.2%，数据来自公司官方发布及SEC 8-K文件。
2. 营收质量与盈利能力：二季度GAAP净收益55.34亿美元，同比微降0.1%，摊薄每股收益2.27美元，同比下滑0.9%；非GAAP净收益70.81亿美元，同比增长5.7%。EBITDA达83亿美元，利润率34.4%。分板块看，创新医药板块运营营收增长6.8%，医疗科技板块增长3.6%。本次更新的财务报表快照为2026年第一季度数据，二季度完整毛利率细节未披露。
3. 现金流与资产负债：年初至今二季度自由现金流约87亿美元，截至2026年第一季度末，现金及等价物217亿美元，总债务550亿美元，净债务333亿美元，数据来自SEC 8-K及更新财务报表。
4. 上调全年指引：公司将2026年全年非GAAP调整后每股收益指引中值上调至11.68美元，较此前提升0.13美元，同比增长8.2%；报告营收中值上调至1011亿美元，同比增长7.3%。
5. GAAP与非GAAP差异：公司未提供GAAP口径全年指引，因无法合理预估法律诉讼等不确定项目；二季度GAAP与非GAAP每股收益差异主要来自无形资产摊销及特殊项目。
6. 管理层点评：管理层称二季度业绩验证了产品组合与管线实力，剔除STELARA后营收实现双位数增长，DARZALEX销售额超40亿美元，TREMFYA同比增长71%，CAPLYTA新患者启动同比增122%，医疗科技板块VARIPULSE装机量突破8.5万例。
7. 未披露信息：尚未披露分板块GAAP营收细节、积压订单、递延收入、资本支出明细、细分需求与定价数据，以及完整的季度GAAP财务拆分。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。